Might 6th (Tel-Aviv): The MedInfuze IvyLife infusion pump was introduced to be a part of the Rakia area technological mission in collaboration with the Israel Aerospace Medication Institute (IAMI).
The IvyLife infusion pump, developed by Dr. Ami Glicksman, a plastic surgeon and innovator, is a miniature, transportable, battery-operated with IoT capabilities infusion pump that goals to exchange the standard infusion pump within the hospital, residence care setting, navy, and subject setting. The brand new pump is gravity impartial and due to this fact appropriate for use in area or below the water. Because of its small measurement and low weight the gadget it’s optimum for any subject and navy use bringing the superior IV pump resolution out of the hospital into any medic backpack. That is the primary resolution launched for such wants.
Dr. Ami Glicksman, MedInfuze founder and CEO, explains the 5 components for achievement. “The IvyLife infusion pump permits affected person’s free mobility, distant cloud E-Well being management and monitoring, web of issues connectivity with very good affected person security and superior remedy QA. The revolutionary IvyLife 150g gadget pump seems like a smartphone, managed by a smartphone, and is well related to the affected person medical information. It permits the caretaker to regulate and supervise the medical remedy. Being gravity impartial, the pump and fluid bag could be positioned in a pocket whereas the affected person pursues each day life actions.”
Dr. Eran Schenker, the Chief Medical Innovation Officer at IAMI, states: “MedInfuze IvyLife infusion pump particular design by Dr. Glicksman makes it appropriate for microgravity setting area mission on board the Worldwide House Station, moon base and lengthy area mission to Mars as effectively in a Mars base”.
MedInfuze Ltd. is a startup enterprise in Israel. After the acceptance to be examined within the Worldwide House Station by Mr. Eitan Stibbe, the second Israeli in area, the corporate is shifting gear and advancing its R&D actions. The corporate is at present elevating funds to assist these actions.
For additional info contact: Ami Glicksman, MD MedInfuze Ltd., Israel M: +972 54 240 2401 Electronic mail: firstname.lastname@example.org or email@example.com